Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

crizotinib

Roche Basel Switzerland

Roche builds on Immunocore ImmTAC deal

Extends partnership to target MAGE-A4 protein tumours

- PMLiVE

AZ’s MYSTIC survival data is in – and it’s a bust

Imfinzi failed to achieve OS improvement

- PMLiVE

Roche gains speedy review for Tecentriq in first-line breast cancer

Set to become the first immunotherapy for triple negative breast cancer

Innovation in merger control and the impact on the pharmaceutical sector

Is focusing on pipeline products enough to assess regulatory risks?

The handover: Pfizer reshapes itself for a new era

There is a new leader at the world's biggest pharma company - but just how much is set to change at Pfizer?

- PMLiVE

Pfizer claims rapid FDA nod for Lorbrena

Green light is latest in a string of cancer drug approvals

Roche Basel Switzerland

Roche and AbbVie prepare to move Venclexta into first-line CLL

Data shows an extended PFS compared to those on Gazyva plus chlorambucil chemo

- PMLiVE

Novartis and Pfizer to collaborate on NASH combinations

Big pharma giants target nascent multi-billion market

- PMLiVE

In conversation with Pfizer’s Erik Nordkamp

Pfizer’s UK managing director and newly appointed ABPI President talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe

- PMLiVE

Roche’s new flu pill Xofluza approved in US

First novel treatment in decades, but hasn't shown superiority to Tamiflu

Roche Basel Switzerland

Roche preps new Kadcyla filings after phase 3 trial win

Says the drug significantly reduced IDFS in women with residual disease

- PMLiVE

Ocrevus surge keeps Roche smiling in Q3

MS drug is performing well, but immuno-oncology contender is in the doldrums

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links